^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
anti-CD19/CD22 CAR-T cells
i
Other names: anti-CD19/CD22 CAR-T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Hrain Biotech
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
1year
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL (clinicaltrials.gov)
P1, N=19, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | Trial completion date: Aug 2022 --> Nov 2023 | Trial primary completion date: Aug 2022 --> Nov 2023
Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
1year
Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients (clinicaltrials.gov)
P1, N=15, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
dasatinib • cyclophosphamide • anti-CD19/CD22 CAR-T cells
2years
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients (clinicaltrials.gov)
P1, N=20, Recruiting, Hrain Biotechnology Co., Ltd.
New P1 trial
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • CD22 (CD22 Molecule) • IL15 (Interleukin 15)
|
CD22 positive
|
anti-CD19/CD22 CAR-T cells
over2years
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL (clinicaltrials.gov)
P1, N=18, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N=10 --> 18
Enrollment change • CAR T-Cell Therapy • Minimal residual disease
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
over2years
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL (clinicaltrials.gov)
P1, N=10, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jul 2022
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
almost3years
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. (clinicaltrials.gov)
P1, N=18, Not yet recruiting, Hrain Biotechnology Co., Ltd.
New P1 trial
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • CD22 (CD22 Molecule) • IL15 (Interleukin 15)
|
CD22 positive
|
anti-CD19/CD22 CAR-T cells
Share via
